Results from a Phase IIb 24-week clinical trial show that Atacicect is safe and may benefit people with high levels of disease activity.
There has been significant progress, not only in awareness, but also in lupus research and advocacy efforts to secure additional research funding for lupus.
Benlysta SC is the first self-injection lupus treatment that can administered at home once per week.
This week, LFA-supported researchers will share results of a study that could help expedite the delivery of new and safer therapies to people with lupus.
Trial results offer hope of a more effective and tolerable treatment option to manage lupus-related kidney disease.
The year-long initiative to make research on lupus treatments more inclusive and effective formally began on July 1.
The provision was approved by the U.S. House of Representatives' Appropriations Committee.
Lupus organizations announce groundbreaking collaborative initiative to inform lupus drug development.